We have located links that may give you full text access.
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
A novel potassium oxalate-containing tooth-desensitising mouthrinse: a comparative in vitro study.
Journal of Dentistry 2013 July
OBJECTIVE: To compare the efficacy of a new potassium oxalate (KO)-containing mouthrinse [Listerine® Advanced Defence Sensitive (LADS)] in reducing dentine permeability and occluding open dentinal tubules versus other desensitising products.
METHODS: The permeability of acid-etched dentine disks was measured by hydraulic conductance; dentine surfaces were examined by scanning electron microscopy and energy-dispersive X-ray spectroscopy. The KO concentration was optimised for tubule occlusion by screening formulations containing 0.0-2.0% KO (n=5 disks per concentration). The optimal formulation was compared with five commercial products with non-oxalate occlusion technologies. After establishing the baseline permeability of acid-etched dentine disks, disks (n=6 per product) were randomly treated with the desensitising products (12 treatments, each 60 s, alternated with distilled-water rinses) and permeability was measured at intervals. Occluded disks were acid challenged. All experiments were conducted at room temperature. An unpooled, two-tailed t test was performed to assess between-treatment differences in relative residual permeability.
RESULTS: The optimal concentration of KO in LADS was 1.4%, which provided ≈ 100% reduction in dentine permeability after nine treatments. Only LADS reduced permeability to zero and was significantly more effective in reducing dentine permeability than the other products (p ≤ 0.033 vs all other test products). All products partially occluded dentine. The occlusion associated with LADS was substantially more stable in resisting acid challenge versus Colgate® Sensitive Pro-Relief mouthrinse (p=0.054) and significantly more stable versus all other test products (p ≤ 0.045), as determined by dentine permeability.
CONCLUSION: LADS was significantly more effective in occluding open dentinal tubules versus other desensitising products.
CLINICAL SIGNIFICANCE: LADS provides fast, complete and stable intratubular occlusion of patent dentinal tubules.
METHODS: The permeability of acid-etched dentine disks was measured by hydraulic conductance; dentine surfaces were examined by scanning electron microscopy and energy-dispersive X-ray spectroscopy. The KO concentration was optimised for tubule occlusion by screening formulations containing 0.0-2.0% KO (n=5 disks per concentration). The optimal formulation was compared with five commercial products with non-oxalate occlusion technologies. After establishing the baseline permeability of acid-etched dentine disks, disks (n=6 per product) were randomly treated with the desensitising products (12 treatments, each 60 s, alternated with distilled-water rinses) and permeability was measured at intervals. Occluded disks were acid challenged. All experiments were conducted at room temperature. An unpooled, two-tailed t test was performed to assess between-treatment differences in relative residual permeability.
RESULTS: The optimal concentration of KO in LADS was 1.4%, which provided ≈ 100% reduction in dentine permeability after nine treatments. Only LADS reduced permeability to zero and was significantly more effective in reducing dentine permeability than the other products (p ≤ 0.033 vs all other test products). All products partially occluded dentine. The occlusion associated with LADS was substantially more stable in resisting acid challenge versus Colgate® Sensitive Pro-Relief mouthrinse (p=0.054) and significantly more stable versus all other test products (p ≤ 0.045), as determined by dentine permeability.
CONCLUSION: LADS was significantly more effective in occluding open dentinal tubules versus other desensitising products.
CLINICAL SIGNIFICANCE: LADS provides fast, complete and stable intratubular occlusion of patent dentinal tubules.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app